Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.60 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.60 |
| ▸ | REN | P00797 | 3/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152879 | 1.00 | CTSK (0.60) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL13263448 | 0.88 | CTSK (0.48) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL12890750 | 0.88 | CTSK (0.61) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL14225360 | 0.88 | CTSK (0.61) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL7433744 | 0.88 | CTSK (0.61) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL11167394 | 0.87 | CTSK (0.55) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL7160678 | 0.87 | CTSK (0.57) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL5552792 | 0.85 | REN (0.53) | CTSKCTSSCTSLCTSBREN | |
| Hydrazine SCHEMBL8410651 | 0.85 | CTSL (0.62) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL17559 | 0.84 | CTSL (0.66) | CTSKCTSSCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-19 | — | — | US | disclosed |
| CN-116874515-B | Amino acid-BSH targeted hybrid compound, and preparation method and application thereof | 重庆高硼生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118406439-B | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118406439-A | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230270889-A1 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | Capital Medical University (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-3118211-B1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA-AND/OR DNA-CONTAINING VIRUSES AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2022-10-12 | — | — | EP | disclosed |
| EP-3897560-B1 | COMPOSITION COMPRISING OXALAMIDE GELATORS AND VEGETABLE OIL | RUDJER BOSKOVIC INST (HR) | 2022-06-29 | — | — | EP | disclosed |
| US-20220023179-A1 | COMPOSITION COMPRISING OXALAMIDE GELATORS AND VEGETABLE OIL | RUDJER BOSKOVIC INSTITUTE (HR) | 2022-01-27 | — | — | US | disclosed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0804180-A1 | METHOD OF INHIBITING CATHEPSIN K | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997016177-A9 | METHOD OF INHIBITING CATHEPSIN K | — | 1997-07-24 | — | — | WO | disclosed |
| WO-1997016177-A1 | METHOD OF INHIBITING CATHEPSIN K | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | AARS1, NSUN3, RNGTT | CTSK 1178/4885CTSS 481/4885CTSL 691/4885 |
| US-20220023179-A1 | COMPOSITION COMPRISING OXALAMIDE GELATORS AND VEGETABLE OIL | OAT, OTC, ODC1 | CTSK 2499/4885CTSS 3138/4885CTSL 4282/4885 |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | SERPINB1, PREP, PRCP | CTSK 73/4885CTSS 44/4885CTSL 20/4885 |
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | CTSK 1178/4885CTSS 481/4885CTSL 691/4885 |
| US-20230270889-A1 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | SLC7A5, BCAT2, BCAT1 | CTSK 2777/4885CTSS 3779/4885CTSL 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.